MDS Profit Hurt by Restructuring, FDA Review TORONTO, March 8 - MDS Inc. , a company providing a range of products and services to the global life sciences markets, today reported its first quarter ...
There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation. Patients who ...
Roger M. Lyons, MD, Discusses 10-Year Review of MDS Patient Data From the Community Oncology Setting
Evidence-Based Oncology™️ spoke with Lyons about the creation of this real-world data set and the pros and cons of different treatments for MDS. Evidence-Based Oncology™️ (EBO) spoke with Lyons about ...
Myelodysplastic syndromes (MDS) are blood cancers caused by an insufficient production of healthy blood cells. Production of irregular cells leads to anemia, where the body’s organs and tissues don’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results